Myelodysplastic Syndrome with Excess Blasts
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndrome with Excess Blasts.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm [Phase 2]
Clinical trial update of a Phase 2 study evaluating venetoclax in combination with ASTX727 (oral decitabine/cedazuridine) for chronic myelom…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia [Phase 1, Phase 2]
This clinical trial update reports a Phase 1/2 study of the combination of vorinostat and azacitidine in patients with myelodysplastic syndr…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts [Phase 1]
Phase 1 clinical trial evaluating TAK-243 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes with increased bla…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts [Phase 1]
Phase 1 study evaluating talazoparib for cohesin-mutated acute myeloid leukemia and myelodysplastic syndrome with excess blasts; the trial i…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome [Phase 2]
This Phase 2 clinical trial investigates the combination of azacitidine and enasidenib for IDH2-mutant myelodysplastic syndrome and is curre…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD [Phase 2]
Phase 2 clinical trial assessing selective depletion of CD45RA+ T cells from allogeneic stem cell grafts to prevent graft-versus-host diseas…
-
CLINICAL_TRIALS trial_result · 2025-01-01Clinical Trial Update: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers [Phase 2]
Phase 2 trial evaluating cord blood transplant with Dilanubicel for HIV-positive hematologic cancers; the study was terminated and results w…
-
CLINICAL_TRIALS trial_result · 2020-10-22Clinical Trial Update: Allogenic NK Cell Transfusion Azacitidine MDS-EB [Phase 1, Phase 2]
Clinical trial update investigating allogeneic NK cell transfusion with azacitidine in MDS-EB, spanning Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2020-01-03Clinical Trial Update: Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT [Phase 2, Phase 3]
A phase 2/3 trial evaluating low-dose azacitidine with a short-term CAG regimen as a bridging treatment before allogeneic hematopoietic stem…
-
CLINICAL_TRIALS trial_result · 2016-03-22Clinical Trial Update: Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia [Phase 2]
A Phase 2 trial investigates adding lenalidomide or vorinostat to azacitidine in higher-risk myelodysplastic syndromes or chronic myelomonoc…
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome [Phase 1]
Phase 1 clinical trial update (completed) of PS-341 (bortezomib) in patients with refractory or relapsed acute myeloid leukemia, acute lymph…